Market Closed -
Nasdaq
21:00:00 07/05/2024 BST
5-day change
1st Jan Change
65.28
USD
+0.35%
+6.46%
-21.81%
Cytokinetics, Incorporated(NasdaqGS:CYTK) added to S&P 400
Cytokinetics, Incorporated(NasdaqGS:CYTK) added to S&P 400
Cytokinetics Insider Sold Shares Worth $1,012,265, According to a Recent SEC Filing
05-07
MT
Cytokinetics Appoints Sung Lee as CFO
04-26
MT
Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024
04-26
CI
Cytokinetics, Incorporated Announces Chief Financial Officer Changes, Effective May 8, 2024
04-26
CI
Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing
04-09
MT
Sector Update: Health Care Stocks Rise Friday Afternoon
04-05
MT
Cytokinetics Reports Positive Follow-On Data for Prospective Heart Medication; Shares Rise
04-05
MT
Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session
04-05
CI
Cytokinetics, Incorporated(NasdaqGS:CYTK) added to S&P 400 - Biotechnology
03-17
CI
Cytokinetics, Incorporated(NasdaqGS:CYTK) added to S&P 400 Health Care
03-17
CI
Cytokinetics, Incorporated(NasdaqGS:CYTK) added to S&P 400
03-17
CI
Cytokinetics, Incorporated(NasdaqGS:CYTK) dropped from S&P 600
03-17
CI
Cytokinetics, Incorporated(NasdaqGS:CYTK) dropped from S&P 600 Health Care
03-17
CI
Transcript : Cytokinetics, Incorporated Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM
03-13
Mizuho Securities Adjusts Price Target on Cytokinetics to $99 From $103, Maintains Buy Rating
03-06
MT
Transcript : Cytokinetics, Incorporated, Q4 2023 Earnings Call, Feb 27, 2024
02-27
Cytokinetics Q4 Net Loss Narrows, Revenue Decreases; 2024 Outlook Issued
02-27
MT
Earnings Flash (CYTK) CYTOKINETICS INCORPORATED Reports Q4 Revenue $1.7M, vs. Street Est of $13.3M
02-27
MT
Cytokinetics, Incorporated Provides Revenue Guidance for 2024
02-27
CI
Cytokinetics, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023
02-27
CI
Cytokinetics, Incorporated Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
02-27
CI
Cytokinetics Insider Sold Shares Worth $960,625, According to a Recent SEC Filing
02-13
MT
Cytokinetics Insider Sold Shares Worth $2,585,497, According to a Recent SEC Filing
02-06
MT
Cytokinetics Insider Sold Shares Worth $994,625, According to a Recent SEC Filing
02-02
MT
Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024
02-02
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.
More about the company
Last Close Price
65.28
USD
Average target price
92.94
USD
Spread / Average Target
+42.38%
Consensus
1st Jan change
Capi.
-21.81% 6.82B +10.44% 106B +0.82% 104B +6.72% 23.25B -13.89% 22.5B -6.64% 18.7B -37.26% 17.95B -10.98% 16.99B +8.67% 14.26B +41.08% 12.76B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1